Placebo-controlled trial of lamotrigine added to conventional and atypical antipsychotics in schizophrenia

Biological Psychiatry
Ilana KremerUriel Heresco-Levy

Abstract

Lamotrigine, a novel anticonvulsant drug having modulatory effects on glutamatergic neurotransmission, improves mood and cognition parameters in bipolar disorder. Recent studies suggest that when added to clozapine, lamotrigine treatment may result in significant positive symptoms reductions in schizophrenia. Similar effects were not observed in an open trial in which lamotrigine was used as adjuvant to nonclozapine antipsychotics. Thirty-eight treatment-resistant schizophrenia inpatients receiving conventional and atypical antipsychotics enrolled in a 10-week, double-blind, placebo-controlled study, in which they were randomized in a 2:1 ratio to receive adjuvant treatment with lamotrigine, gradually titrated to a 400 mg/day dose, or placebo. Of these, 31 completed the trial. Measures of clinical efficacy and side effects were determined every other week. Serum levels of amino acids were assessed at the beginning and end of the study. In primary last observation carried forward analysis, no statistically significant between-group differences were observed; however, the completers' analyses revealed that lamotrigine treatment resulted in significant (p < or = .05) reductions in positive and general psychopathology symptoms, as ...Continue Reading

References

Jan 1, 1975·Progress in Biophysics and Molecular Biology·G Roy
Jan 11, 1991·Archives of General Psychiatry·W T CarpenterA Breier
Jan 1, 1987·Schizophrenia Bulletin·S R KayL A Opler
Jan 1, 1970·Acta Psychiatrica Scandinavica. Supplementum·G M Simpson, J W Angus
Jul 1, 1995·The American Journal of Psychiatry·R J BaldessariniF Centorrino
Oct 26, 1999·Archives of General Psychiatry·S M DursunH Milliken
Apr 6, 2001·Clinical Neuropharmacology·S I DeutschJ Mastropaolo
Sep 15, 2001·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·A C LahtiC A Tamminga
Mar 9, 2002·The Journal of Neuropsychiatry and Clinical Neurosciences·G SabaD Januel
Jun 29, 2002·Journal of Child Neurology·Michael DuchownyUNKNOWN LAMICTAL Pediatric Study Group
Jul 2, 2002·Archives of General Psychiatry·John H KrystalBita Moghaddam
Dec 10, 2002·The Journal of Clinical Psychiatry·David M Labiner
Sep 12, 2003·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Maria B Isaac, Michael T Isaac
Feb 1, 1960·Journal of Neurology, Neurosurgery, and Psychiatry·M HAMILTON
Nov 25, 2003·The Journal of Clinical Psychiatry·Joseph R CalabreseUNKNOWN Lamictal 605 Study Group

❮ Previous
Next ❯

Citations

Jul 8, 2005·Psychopharmacology·Charles H LargeDonald C Goff
Jan 7, 2006·The Psychiatric Quarterly·Deanna L KellyCharles M Richardson
Feb 11, 2012·The Psychiatric Quarterly·Adam Daniel Zavodnick, Rizwan Ali
Aug 11, 2007·International Clinical Psychopharmacology·A Carlo AltamuraHerbert Y Meltzer
Aug 27, 2005·The Journal of Pharmacology and Experimental Therapeutics·Jacob C OngMark A Geyer
Oct 14, 2009·Indian Journal of Psychiatry·Chittaranjan Andrade
May 17, 2011·Indian Journal of Pharmacology·Abhishek GhoshSurendra Kumar Mattoo
Sep 2, 2008·Expert Review of Neurotherapeutics·Monsheel SodhiJames Meador-Woodruff
Dec 24, 2008·Expert Review of Neurotherapeutics·Leslie Citrome
Oct 7, 2014·Expert Opinion on Pharmacotherapy·Maria Rosaria A MuscatelloRocco Zoccali
Sep 4, 2008·Expert Opinion on Emerging Drugs·Ofer AgidGary Remington
Jan 25, 2011·Expert Opinion on Pharmacotherapy·Scott P Van Sant, Peter F Buckley
Sep 22, 2005·The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry·Peter FalkaiUNKNOWN WFSBP Task Force on Treatment Guidelines for Schizophrenia
Sep 13, 2011·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Stefano PorcelliAlessandro Serretti
Oct 3, 2009·Medical Hypotheses·Iria Alvarez-SilvaJavier Alvarez-Rodriguez
Jun 3, 2008·Progress in Neuro-psychopharmacology & Biological Psychiatry·Mark J HuntStefan Kasicki
Dec 3, 2005·Child and Adolescent Psychiatric Clinics of North America·Harvey N KranzlerSanjiv Kumra
Nov 24, 2005·Progress in Neuro-psychopharmacology & Biological Psychiatry·Harriet J WilliamsSerdar M Dursun
Nov 3, 2005·Expert Opinion on Emerging Drugs·Uriel Heresco-Levy
Jul 15, 2005·Expert Opinion on Pharmacotherapy·Zubin Bhagwagar, Guy M Goodwin
Jul 28, 2012·The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry·Alkomiet HasanUNKNOWN World Federation of Societies of Biological Psychiatry (WFSBP) Task Force on Treatment Guidelines for Schizophrenia
Jun 28, 2015·Pharmacology & Therapeutics·Evangelia M TsapakisFrank I Tarazi
Jan 26, 2011·Schizophrenia Research·Maria Rosaria A MuscatelloRocco A Zoccali
Dec 12, 2012·Schizophrenia Research·Sefa VayısoğluM Kâzım Yazıcı
Oct 25, 2012·Epilepsy & Behavior : E&B·Piero Perucca, Marco Mula
Feb 5, 2011·Journal of Psychopharmacology·Thomas R E Barnes, UNKNOWN Schizophrenia Consensus Group of British Association for Psychopharmacology
Feb 3, 2007·American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics : the Official Publication of the International Society of Psychiatric Genetics·H Le-NiculescuA B Niculescu
Apr 28, 2006·Current Opinion in Psychiatry·Peter F Buckley, Nitin Shendarkar
Dec 6, 2008·Journal of Psychiatric Practice·Anand K Pandurangi, Alican Dalkilic
Nov 16, 2007·Journal of Clinical Psychopharmacology·Donald C GoffElizabeth L Webster
Apr 5, 2005·Harvard Review of Psychiatry·Leslie CitromeStephen M Stahl
Oct 21, 2006·The Cochrane Database of Systematic Reviews·T S Premkumar, J Pick

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here